Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Breast cancer drug Avastin loses FDA support

According to a Food and Drug Administration (FDA) announcement last Friday, the cancer drug Avastin should not be used to treat breast cancer that has spread to other organs because it doesn't help patients enough to justify its risky side effects.

21 Nov 2011

Avastin drug not safe and effective for breast cancer patients: FDA Commissioner

FDA Commissioner Margaret A. Hamburg, M.D., said today she is revoking the agency's approval of the breast cancer indication for Avastin (bevacizumab) after concluding that the drug has not been shown to be safe and effective for that use.

19 Nov 2011

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Genentech, a member of the Roche Group, announced today that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States.

18 Nov 2011

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

An anti-malaria drug used for more than 60 years is now being studied for use in breast cancer patients whose disease has not responded to traditional chemotherapy treatment.

18 Nov 2011

Biothera completes enrollment in Imprime PGG Phase II combination study on NSCLC

EBiothera's Phase II non-small cell lung cancer (NSCLC) clinical trial evaluating Imprime PGG administered in combination with cetuximab (Erbitux), carboplatin and paclitaxel has met its goal of 90 patients and is fully enrolled, the company announced today.

17 Nov 2011

Drug-coated balloon restores blood flow in narrowed bare metal stent

A drug-coated balloon inserted in a narrowed bare metal stent is a promising therapy for restoring blood flow, according to research presented at the American Heart Association's Scientific Sessions 2011.

17 Nov 2011

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

Oncolytics Biotech Inc. today announced that positive results from a Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

14 Nov 2011

New data on TetraLogic's TL32711 cancer drug to be presented at AACR-NCI-EORTC conference

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced presentations of new data on its Smac mimetic drug candidate TL32711 at the 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in San Francisco.

14 Nov 2011

Positive results from BIOTRONIK Pantera Lux Paclitaxel Releasing Balloon study presented at TCT 2011

Six-month results from the DELUX registry and 12-month results from the PEPPER study, both demonstrating excellent safety and efficacy results for the Pantera Lux Paclitaxel Releasing Balloon, were presented on Tuesday and Wednesday at the Transcatheter Cardiovascular Therapeutics (TCT 2011) conference by Dr. Ralph Toelg, MD, Segeberger Heart Center Clinic, Bad Segeberg, Germany, and Prof. Christoph Hehrlein, MD, University Medical Center, Freiburg, Germany, respectively.

10 Nov 2011

Infinity third quarter total revenue increases marginally to $23.3 million

Infinity Pharmaceuticals, Inc. today highlighted its recent clinical and business progress and announced its third quarter 2011 financial results.

9 Nov 2011

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2011, and provided a business update.

9 Nov 2011

Boston Scientific reports positive long-term data from PERSEUS clinical program

Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.

9 Nov 2011

Scientists achieve major step toward goal of producing synthetic Taxol

Taxanes are a family of compounds that includes one of the most important cancer drugs ever discovered, Taxol, among other cancer treatments. But the difficulty producing these complex molecules in the lab has hampered or blocked exploration of the family for further drug leads. Now, a group of Scripps Research Institute scientists has successfully achieved a major step toward the goal of synthetically producing Taxol and other complex taxanes on a quest to harness chemical reactions that could enable research on previously unavailable potential drugs.

7 Nov 2011

Medtronic highlights scientific sessions of interest on program for TCT 2011

Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.

From Medtronic 5 Nov 2011

Cancer drug shortage relates to economics

A perspective in this week's New England Journal of Medicine outlines this connection. Meanwhile, a House Democrat ramps up his investigation into the "gray market" and how it is contributing to the shortage.

4 Nov 2011

Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.

31 Oct 2011

CERT gene silencing makes breast cancer cells more sensitive to drugs

CANCER RESEARCH UK scientists have discovered that switching off a gene called CERT makes breast cancer cells more sensitive to a range of drugs. The research is published in the Journal of Pathology.

21 Oct 2011

USPTO issues patent to Rexahn's new anti-cancer arylisoquinolinamine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled "5, 6, or 7-Substituted-3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof."

13 Oct 2011

Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer patients.

12 Oct 2011

Cannabidiol could prevent onset of pain associated with chemotherapy drugs

A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University's School of Pharmacy.

7 Oct 2011

Paclitaxel News and Research

Further Reading

Breast cancer drug Avastin loses FDA support

Avastin drug not safe and effective for breast cancer patients: FDA Commissioner

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

Biothera completes enrollment in Imprime PGG Phase II combination study on NSCLC

Drug-coated balloon restores blood flow in narrowed bare metal stent

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

New data on TetraLogic's TL32711 cancer drug to be presented at AACR-NCI-EORTC conference

Positive results from BIOTRONIK Pantera Lux Paclitaxel Releasing Balloon study presented at TCT 2011

Infinity third quarter total revenue increases marginally to $23.3 million

CytRx reports net loss of $0.6 million for third quarter 2011

Boston Scientific reports positive long-term data from PERSEUS clinical program

Scientists achieve major step toward goal of producing synthetic Taxol

Medtronic highlights scientific sessions of interest on program for TCT 2011

Cancer drug shortage relates to economics

Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors

CERT gene silencing makes breast cancer cells more sensitive to drugs

USPTO issues patent to Rexahn's new anti-cancer arylisoquinolinamine compounds

Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer

Cannabidiol could prevent onset of pain associated with chemotherapy drugs

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News